Your Stomach on a GLP-1: Gastroparesis, Nausea, and What the Evidence Actually Says

Your stomach on a GLP-1: gastroparesis, nausea, and what the data says

Somewhere around week two on Wegovy, you Google "GLP-1 gastroparesis" at 2 a.m. because your stomach has been making sounds you've never heard before and a CNN segment from 2023 won't stop replaying. You find 14 million results, half of them terrifying, half of them dismissive. Neither half is particularly useful.

About 44% of people on semaglutide 2.4 mg report nausea during the STEP 1 trial (Wilding et al., NEJM 2021, n = 1,961). Constipation hits 24%. Vomiting, another 24%. These are not rare. They're also not the same as gastroparesis, which is a distinct clinical diagnosis with a specific definition and a much smaller risk profile. The gap between "my stomach is unhappy" and "I have a motility disorder" is enormous — and getting the two confused is costing people sleep, money, and sometimes their medication.

How GLP-1s talk to your gut

The mechanism is straightforward and it's not a bug. GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide — slow gastric emptying. That's part of how they work. When food stays in your stomach longer, you feel full sooner, eat less, and experience a gentler glucose curve after meals. Dr. Daniel Drucker at the University of Toronto, who has studied GLP-1 physiology for three decades, has described this as a feature, not a failure mode.

Tirzepatide slows gastric emptying by up to 70% at peak plasma concentration (Urva et al., Clinical Pharmacology & Therapeutics 2022). Semaglutide produces a somewhat smaller delay. Both effects are dose-dependent and both attenuate over time — meaning your stomach adjusts. By weeks 8 to 12 on a stable dose, gastric emptying typically returns closer to baseline, even though appetite suppression persists through central nervous system pathways.

A few things worth separating:

1. Delayed emptying is the mechanism, not a complication. Your stomach slowing down is the drug doing its job.
2. The delay is temporary at each dose tier. It peaks during the first weeks of a new dose and fades.
3. Persistent, severe delay — the kind that meets clinical criteria for gastroparesis — is a different situation entirely.

Nausea: the number everyone gets wrong

Nausea is the single most common GI side effect across every GLP-1 on the market. It's also the most misunderstood. The 44% number from STEP 1 is an across-the-trial cumulative incidence — it counts every patient who reported nausea at any point during 68 weeks at any dose. It does not mean 44% of people are nauseated at any given time.

The real pattern looks more like this: nausea peaks during weeks 1 to 4 of each dose escalation, is usually mild to moderate, and resolves for most people by weeks 8 to 12 on a stable dose. In STEP 1, the majority of nausea episodes lasted less than a week. The discontinuation rate due to GI side effects across the STEP program was about 4 to 7%.

Tirzepatide trends lower. SURMOUNT-1 (Jastreboff et al., NEJM 2022, n = 2,539) reported nausea in 24 to 33% of participants depending on dose tier, vomiting in 9 to 13%, and constipation in 17 to 23%. Discontinuation for adverse events was about 4 to 7% across dose groups.

The older GLP-1, liraglutide (Saxenda), sits in the middle. The SCALE trial reported nausea at 39%, constipation at 19%, and diarrhea at 21%.

What nausea on a GLP-1 usually feels like isn't classic stomach-flu nausea. It's closer to the feeling of having eaten Thanksgiving dinner 20 minutes ago — persistent, heavy fullness that tips into queasiness when you eat too much, too fast, or too rich. Portion size is the single biggest lever you can pull.

Why some people breeze through and others don't

We don't fully know. Body composition, baseline gastric motility, genetics of GLP-1 receptor expression, and even gut microbiome differences all probably contribute. What the data does tell us is that slow titration dramatically reduces GI side effects. People who skip dose levels or titrate faster than the label schedule have more nausea, more vomiting, and higher dropout rates. The Wegovy schedule (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, four weeks per step) exists for exactly this reason.

Gastroparesis: separating the clinical diagnosis from the media cycle

In August 2023, CNN ran a segment that put GLP-1 gastroparesis fears on the map. CBS followed. Social media amplified. Suddenly, every Reddit thread about slow digestion on Ozempic included the word "gastroparesis" — and a lot of people got scared.

The evidence tells a more specific story.

A 2023 study from Cedars-Sinai (Sodhi et al., published in JAMA) examined insurance claims data and found a hazard ratio of 3.67 for gastroparesis diagnosis in GLP-1 receptor agonist users compared to non-users. That sounds alarming, and the headlines reflected it. But context matters.

The baseline rate of gastroparesis is low. In the general population, it's roughly 10 to 25 per 100,000. Even with a 3.67x increase, the absolute risk remains small. An HR of 3.67 applied to a rare event doesn't produce a common event.

Claims data captures diagnostic codes, not confirmed disease. If a clinician evaluates someone on a GLP-1 for slow emptying and codes it as gastroparesis during workup, it appears in claims data — whether or not a formal gastric emptying study confirmed it, and whether or not the symptoms persisted after stopping the drug.

Delayed gastric emptying from GLP-1s is usually reversible. Clinical gastroparesis is typically defined as a chronic condition with delayed emptying on scintigraphy or breath test, plus symptoms, in the absence of mechanical obstruction. Drug-induced delayed emptying that resolves when you stop or reduce the medication doesn't meet most gastroenterologists' definition of true gastroparesis.

In January 2024, the FDA updated GLP-1 agonist labels to include ileus (intestinal blockage) as a reported adverse event and flagged gastroparesis-like symptoms. This was a signal-detection response — the agency acknowledging reports — not a causal determination. The label change is worth knowing about, but it doesn't mean gastroparesis is a common outcome of GLP-1 therapy.

Dr. Michael Camilleri at Mayo Clinic, one of the world's leading gastroparesis researchers, has been careful to distinguish between drug-induced delayed emptying and idiopathic gastroparesis. In clinical discussions through 2024 and 2025, he's noted that the vast majority of GLP-1-associated gastric delay resolves with dose reduction or discontinuation — a pattern inconsistent with the natural history of true gastroparesis.

Bowel obstruction and ileus: rare, but on the label

The FDA's 2024 label update also flagged intestinal obstruction. These cases are rare. In the FAERS (FDA Adverse Event Reporting System) database, reports of bowel obstruction in GLP-1 users exist but represent a small fraction of total adverse event reports, and many occurred in patients with pre-existing GI conditions, prior abdominal surgeries, or concomitant opioid use — all independent risk factors.

Ileus — where the intestines temporarily stop moving — has been reported in post-marketing surveillance. Most cases resolved with drug discontinuation and supportive care. The clinical profile is consistent with an exaggeration of the known pharmacological effect (gut slowing) rather than a novel toxicity mechanism.

Three risk factors that increase the chance of serious GI events on GLP-1 therapy:

• Prior abdominal surgery — adhesions can turn slowed motility into obstruction
• Concurrent opioid use — opioids already slow the gut; adding a GLP-1 compounds the effect
• Pre-existing gastroparesis or severe diabetic neuropathy — an already-compromised gut handles additional slowing poorly

If you have any of these, your prescriber should know before you start. It doesn't necessarily mean you can't use a GLP-1, but it means closer monitoring and potentially slower titration.

Sulfur burps, constipation, and diarrhea — the daily reality

These won't make CNN. They also won't kill you. But they're the side effects that make or break whether someone sticks with treatment past month three.

Sulfur burps

If you've been on r/Ozempic or r/Zepbound for more than five minutes, you've seen the sulfur-burps threads. The clinical literature hasn't caught up — there are no large studies specifically on hydrogen sulfide eructation during GLP-1 therapy. But the mechanism is plausible: slowed gastric emptying gives gut bacteria more time to ferment food, producing hydrogen sulfide gas. Foods high in sulfur compounds — eggs, broccoli, garlic, red meat — tend to be the worst offenders.

Practical fixes that the community reports working:

• Smaller, more frequent meals
• Limiting high-sulfur foods (especially eggs and cruciferous vegetables)
• Taking simethicone (Gas-X) before meals
• Staying hydrated — dehydration concentrates gut contents and slows motility further
• Timing meals earlier in the day, when gastric motility is naturally higher

Constipation

Constipation rates: Wegovy 24% (STEP 1), Zepbound 17 to 23% (SURMOUNT-1 by dose), Saxenda 19% (SCALE). This one is dose-dependent, cumulative, and partly behavioral — people on GLP-1s eat less, which means less fiber and less fluid, which means less bulk moving through the colon.

First-line management: fiber supplementation (psyllium husk or methylcellulose, 15 to 25 g per day), adequate water (aim for 2 to 3 liters daily), and physical activity. If that's not enough, polyethylene glycol (MiraLAX) is safe for regular use. Stimulant laxatives should be a last resort and not a daily habit.

Diarrhea

Diarrhea rates: Wegovy 30%, Zepbound 17%, Saxenda 21%. It tends to be more common in the first few weeks and can alternate with constipation in the same patient. The pattern of "diarrhea early, constipation later" that appears in the Wegovy side effects guide is a pattern clinicians frequently observe.

If diarrhea persists beyond week 8 on a stable dose, that's worth bringing up with your prescriber. Persistent diarrhea can cause electrolyte imbalances, dehydration, and make the medication genuinely hard to live with.

GI side effects across drugs: the comparison table

These numbers are cumulative incidence rates from the pivotal trials. They represent "reported at any point during the trial at any dose," not "happening right now."

Two patterns worth noticing. First, tirzepatide runs lower on nausea and vomiting despite being a dual GIP/GLP-1 agonist — the GIP component may have a protective effect on the gut, though the exact mechanism isn't settled. Second, placebo groups report surprisingly high GI side effect rates, which reminds us that background GI symptoms are common in any population.

Evidence-based nausea management: what works, ranked

Here's what the evidence supports, roughly ranked by data quality.

The single most effective intervention is boring: follow the titration schedule and don't eat large, fatty meals. In the first month on a GLP-1 timeline, most nausea episodes cluster in the first 3 to 5 days after each dose increase and resolve within a week.

When to call your doctor — red flags that aren't just nausea

Most GI side effects on GLP-1s are uncomfortable but not dangerous. A small number of situations need prompt attention.

Call your prescriber soon (within 24 to 48 hours) if you experience:

• Nausea or vomiting that prevents you from keeping any food or liquids down for more than 24 hours
• New, persistent constipation that doesn't respond to fiber, fluids, and MiraLAX after 5 to 7 days
• Diarrhea lasting more than 3 days with signs of dehydration (dark urine, dizziness, dry mouth)
• Persistent bloating with inability to pass gas

Go to the ER or call 911 if you experience:

• Severe, sharp abdominal pain — especially if it radiates to your back (possible pancreatitis)
• Complete inability to pass stool or gas for more than 48 hours with worsening abdominal distension (possible bowel obstruction)
• Vomiting blood or blood in stool
• Signs of severe dehydration: confusion, rapid heart rate, very dark or absent urine
• Persistent vomiting (more than 6 episodes in 24 hours) that prevents any oral intake

The pancreatitis signal is the one to remember. GLP-1 labels carry a warning for acute pancreatitis. The STEP and SURMOUNT programs reported pancreatitis at low rates (under 0.5%), but when it happens, it's serious. Epigastric pain boring through to the back, often after eating, often with vomiting — that's an ER visit, not a wait-and-see situation.

Questions to bring to your next appointment

If GI side effects are part of your GLP-1 experience, showing up with specific questions saves both you and your prescriber time. A few worth asking:

• "My nausea is worst on days 2 to 4 after the injection — would switching my injection day help me manage it around work or social events?"
• "I've been on this dose for 6 weeks and the nausea hasn't improved. Should we stay here longer before titrating up, or consider switching to a different GLP-1?"
• "I had a prior abdominal surgery. Does that change how we should think about my constipation symptoms?"
• "I'm on [opioid/anticholinergic/other gut-slowing medication]. Should we adjust anything?"
• "What's the threshold for prescribing ondansetron? I'd rather have it in the drawer before I need it."

These are the kind of questions that get you a better conversation than "I feel sick." Specificity helps. Timing data helps more.

The Mounjaro and Zepbound angle

Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) appears to have a lower GI side-effect burden than semaglutide across head-to-head-adjacent data. The SURMOUNT trials report lower nausea, lower vomiting, and roughly similar constipation rates compared to the STEP trials — even at tirzepatide's highest doses (15 mg), which produced greater weight loss than semaglutide 2.4 mg.

The working hypothesis: tirzepatide's GIP receptor agonism may buffer the GI effects of GLP-1 receptor activation. GIP has its own gastric-emptying effects, and the dual mechanism may produce a smoother ride for the gut. This is still being studied, and nobody has run a head-to-head GI-tolerability trial designed to answer this specific question.

If you're on semaglutide and GI side effects are the limiting factor — not cost, not insurance, not efficacy — a switch to tirzepatide is a reasonable conversation to have. The Mounjaro side effects guide covers the tirzepatide-specific profile in more detail.

What the landscape looks like from here

Three developments are shaping the GI safety conversation for GLP-1s in 2026 and beyond.

Oral GLP-1s change the equation. Orforglipron (Foundayo), Lilly's oral daily GLP-1 approved in April 2026, avoids injection-site issues but still causes nausea in approximately 25 to 35% of trial participants. The GI effect isn't route-dependent — it's receptor-dependent. Oral formulations may adjust the PK curve enough to smooth out some peaks, but they won't eliminate gut effects.

Better titration protocols are coming. Some obesity medicine clinics now offer 8-week dose steps instead of 4-week steps for patients with high GI sensitivity. Others are exploring micro-titration with compounded (non-FDA-approved) formulations, though the regulatory status of compounded GLP-1s remains unsettled after the 2024 shortage resolution. Lilly and Novo Nordisk are both studying modified titration schedules in ongoing trials.

Real-world data is catching up to fear. The 2023 Cedars-Sinai gastroparesis study triggered an appropriate wave of clinical attention. Since then, multiple follow-up analyses — including several European registry analyses — have confirmed that the absolute risk of clinically significant gastroparesis on GLP-1 therapy remains low, that most cases are reversible with dose adjustment or discontinuation, and that the population most at risk (people with pre-existing diabetic neuropathy and prior GI disease) can usually be identified before starting treatment.

The nausea conversation will evolve. The gastroparesis panic has already started to recede as better data arrives. But the daily-reality stuff — sulfur burps, the first week after a dose increase, learning to eat smaller portions when your brain still remembers what a full plate used to look like — that's the real work. Most of this fades. The sulfur burps, the first-week misery after a dose bump — it passes. If it doesn't, that's a conversation worth having before you give up on the medication entirely.

Worth bringing up at your next visit if any of this sounds familiar. Your prescriber has heard it all, and the conversation about managing GI effects is usually more productive than the one about stopping treatment entirely.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app